Is HBIO or PACB more undervalued in 2026?

CirclFi compares Harvard Bioscience, Inc. (HBIO) and Pacific Biosciences of Californ (PACB) using 13 institutional-grade valuation models. HBIO has a Quality of Company score of 5.7/10 while PACB scores 5.7/10.

Which is a better buy — HBIO or PACB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HBIO and PACB valuations compare?

HBIO at $5.88 and PACB at $1.49 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HBIO vs PACB Valuation Comparison 2026 — Intrinsic Value Analysis

HBIO

Laboratory Analytical Instruments

Harvard Bioscience, Inc.

Quality

5.7

out of 10

Value Trap

SAFE

Price

$5.88

Last close

Models

11/13

Active

PACB

Laboratory Analytical Instruments

Pacific Biosciences of Californ

Quality

5.7

out of 10

Value Trap

WARN

Price

$1.49

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	HBIO Fair Value	HBIO Upside	PACB Fair Value	PACB Upside
Bayesian DCF	Intrinsic	$10.78	+83.4%	$2.54	+48.4%
Earnings Power Value	Intrinsic	$14.18	+123.0%	$1.49	-6.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HBIO vs PACB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HBIO vs PACB — Which Stock Is More Undervalued?

HBIO scores higher with a 5.7/10 quality rating vs PACB's 5.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Harvard Bioscience, Inc. (HBIO) and Pacific Biosciences of Californ (PACB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HBIO currently trades at $5.88 with a QOC of 5.7/10, while PACB trades at $1.49 with a QOC of 5.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).